Mebanazine

Identification

Generic Name

Mebanazine

DrugBank Accession Number

DB09248

Background

Mebanazine, also known asActomol, is a monoamine oxidase inhibitor (MAOI) belonging to thehydrazineclass of chemicals. It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.

Type

Small Molecule

Groups

Withdrawn

Structure

3D

Download

MOL SDF 3D-SDF PDB SMILES InChI

类似的结构

Structure for Mebanazine (DB09248)

×

Close

Weight

Average: 136.198
Monoisotopic: 136.100048394

Chemical Formula

C₈H₁₂N₂

同义词

• Mebanazine

Pharmacology

Indication

For the treatment of depression.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The risk or severity of adverse effects can be increased when Mebanazine is combined with 1,2-Benzodiazepine.
Abciximab	The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Abciximab.
Acarbose	Mebanazine may increase the hypoglycemic activities of Acarbose.
Acebutolol	Mebanazine may increase the hypotensive activities of Acebutolol.
Aceclofenac	The risk or severity of hypertension can be increased when Aceclofenac is combined with Mebanazine.
Acemetacin	The risk or severity of hypertension can be increased when Mebanazine is combined with Acemetacin.
苊香豆醇	The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Acenocoumarol.
Acetazolamide	The risk or severity of adverse effects can be increased when Acetazolamide is combined with Mebanazine.
Acetohexamide	Mebanazine may increase the hypoglycemic activities of Acetohexamide.
Acetophenazine	The risk or severity of extrapyramidal symptoms can be increased when Mebanazine is combined with Acetophenazine.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

International/Other Brands

Actomol

Categories

Drug Categories

• Agents that produce hypertension
• Agents that reduce seizure threshold
• Antidepressive Agents
• Central Nervous System Depressants
• Monoamine Oxidase Inhibitors
• Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome

Chemical TaxonomyProvided byClassyfire

Description

This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.

Kingdom

有机compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Not Available

Direct Parent

Benzene and substituted derivatives

Alternative Parents

Alkylhydrazines/Organopnictogen compounds/Hydrocarbon derivatives

Substituents

Alkylhydrazine/Aromatic homomonocyclic compound/Hydrazine derivative/Hydrocarbon derivative/Monocyclic benzene moiety/有机nitrogen compound/Organonitrogen compound/Organopnictogen compound

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

Not Available

Affected organisms

• Humans and other mammals

Chemical Identifiers

UNII

Z5R55CJ4CG

CAS number

65-64-5

InChI Key

HHRZAEJMHSGZNP-UHFFFAOYSA-N

InChI

InChI=1S/C8H12N2/c1-7(10-9)8-5-3-2-4-6-8/h2-7,10H,9H2,1H3

IUPAC Name

(1-phenylethyl)hydrazine

SMILES

CC(NN)C1=CC=CC=C1

References

一般引用

1. Gilmour SJ: Clinical trial of mebanazine--a new monoamine oxidase inhibitor. Br J Psychiatry. 1965 Sep;111(478):899-902. [Article]
2. Barker JC, Jan IA, Enoch MD: A controlled trial of mebanazine ('Actomol') in depression. Br J Psychiatry. 1965 Nov;111(480):1095-100. [Article]
3. Knott F: A preliminary trial of mebanazine in depressive states. J New Drugs. 1965 Nov-Dec;5(6):345-7. [Article]

External Links

PubChem Compound

6179

PubChem Substance

310265151

ChemSpider

5944

ChEBI

134728

ChEMBL

CHEMBL1909283

Wikipedia

Mebanazine

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	10.6 mg/mL	ALOGPS
logP	1.24	ALOGPS
logP	1.33	Chemaxon
logS	-1.1	ALOGPS
pKa (Strongest Basic)	5.33	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	2	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	38.05 Å2	Chemaxon
Rotatable Bond Count	2	Chemaxon
Refractivity	53.93 m3·mol-1	Chemaxon
Polarizability	15.65 Å3	Chemaxon
Number of Rings	1	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	Yes	Chemaxon
医学博士DR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at October 24, 2015 03:57 / Updated at February 21, 2021 18:52